

# 11 OCTOBER 2023

13.50-14.00	OPENING REMARKS OF EHOc 2023 Birol Güvenç, Serdar Bedii Omay, Bülent Zülfikar, Giuseppe Saglio, Osman İlhan	
14.00 - 14.20	Life Time Achivement Award Presentation: Influence of Women on Turkish Hematology	Chair: Birol Guvenç Speaker: Deniz Sargin(Virtual)
14.20-15.20	SESSION 1 - AML	CHAIRS: Zeba Aziz - Serdar Bedii Omay
14.20 - 14.30	State of the Art - Role of Maintenance Therapy in AML	Zeba Aziz
14.30 - 14.50	A Case of AML Given Maintanance Therapy	Mehmet Yılmaz
14.50 - 15.10	Induction Therapy Choices and Responses in a Third World Country: A Single Center Study From Pakistan	Amjad Zafar(Virtual)
15.10 - 15.20	Future Perspectives	Naval Daver(Virtual)
15.20 - 15.40	Life Time Achivement Award Presentation:	Chair:Gamze Tanrıöver Speaker: Robert Peter Gale
15.40-16.10	  <p>SATELLITE SYMPOSIUM The Role of Lenalidomide in the Management of Multiple Myeloma in Light of Clinical Experiences and Future Directions Chair:Mustafa Çetiner Speaker:Tülin Tuğlular</p>	
16.10-16.40	POSTER WALK WITH COFFEE BREAK Chair : Mehmet Hilmi Doğu	
	Biomedical Analysis of Red Blood Cells in Polycythemia Vera, Application of Raman Spectroscopy	Weronika Marzena Lebowa
	The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients With Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-Center Real-Life Study	Müzeyyen Aslaner Ak
	A Rare Cause of Cyanosis: Hemoglobin Kansas	Metban Mastanzade
	A Rare Cause of Lymphadenopathy: Kikuchi Fujimoto	Gülcan Erbaş


16.40-18.00	<b>SESSION 2 - ALL</b>	<b>CHAIRS: Serdar Bedii Omay - Fevzi Altuntaş</b>
16.40-16.50	<b>State of the Art</b>	<b>Giovanni Martinelli(Virtual)</b>
16.50-17.10	<b>Patient 1 - Presentation and Discussion</b>	<b>Birol Güvenç</b>
17.10-17.30	<b>Elderly Ph+ Patient Sound Feasible?</b>	<b>Giovanni Marconi</b>
17.30-17.50	<b>When to Transplant</b>	<b>Sabina Chiaretti / Yes(Virtual) – Elias Jabbour / No (Virtual)</b>
17.50-18.00	<b>Future Perspectives</b>	<b>Elias Jabbour(Virtual)</b>
17.00-18-50	<b>SESSION 3 - SELECTED ORAL COMMUNICATIONS (ADULT HEMATOLOGY)</b>	<b>CHAIRS: Giuseppe Saglio -Osman İlhan</b>
18.00-18.10	<b>Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma (Ikema): Final Overall Survival Analysis</b>	<b>Ecenur Güder Arslan</b>
18.10-18.20	<b>Increased Carotid Intima Media Thickness As an Indicator of Increased Cardiovascular Risk in Patients With Primary Familial Erythrocytosis</b>	<b>Alpay Yeşilaltay</b>
18.20-18.30	<b>New Molecular Targets in Cancer Cell Bioenergetic Pathways</b>	<b>Ivan Tyumin</b>
18.30-18.40	<b>Changes in Mucosa-Associated Invariant T Cells (Mait), Associated Cytokines, and Mr-1+ Cell Number and Phenotype in the Peripheral Blood of Pediatric ITP Patients With and Without Eltrombopag Therapy</b>	<b>Ekrem Ünal</b>

	<b>12 OCTOBER 2023</b>	
08.15-08.45	<b>ORAL COMMUNICATIONS SESSIONS (ADULT HEMATOLOGY)</b>	<b>Chairs: Emin Kaya-Mehmet Ali Uçar</b>
08.15-08.25	<b>Evaluation of Vitamin D Status in Adult Patients With Immune Thrombocytopenia</b>	<b>Rafiye Çiftçiler</b>
08.25-08.35	<b>The Role of Adamts13 Activity Levels on Disease Exacerbation or Relapse in Patients With Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of The Phase 3 Hercules and Post-Hercules Studies</b>	<b>Özgüç Semih Şimşir</b>
08.35-08.45	<b>Ureteral Amyloidosis: A Case Report of Successful Management With Surgery, Radiation, and Chemotherapy</b>	<b>İbrahim Halil Açar(Virtual)</b>

09.00-10.00	<b>ADULT &amp; PEDIATRIC ONCOHEMATOLOGY JOINT (BMT VS CAR T CELL)</b>	<b>CHAIRS: Khalid Halahleh - Oral Nevruz</b>
09.00-09.10	<b>State of the Art</b>	<b>Arnon Nagler(Virtual)</b>
09.10-09.30	<b>Is Hematopoietic Stem Cell Transplantation Necessary to Consolidate Hematological Remission After CAR-T Therapy?</b>	<b>Francesco Saglio</b>
09.30-09.50	<b>Post CAR-T: To Transplant, or Not To Transplant, That's The Question!</b>	<b>Koray Yalçın</b>
09.50-10.00	<b>Future Perspectives</b>	<b>Fatma Visal Okur</b>
10.00-11.00	<b>ADULT &amp; PEDIATRIC HEMATOLOGY ON HEMOGLOBINOPATHIES JOINT SESSION</b>	<b>CHAIRS: Salam Al-Kindi - Fahri Şahin</b>
10.00-10.10	<b>State of the Art</b>	<b>Maria Capellini(Virtual)</b>
10.10-10.30	<b>A Patient Case on Non-Transfusion Dependent Thalassemia</b>	<b>Ali Taher (Virtual)</b>
10.30-10.50	<b>Patient 2 - Presentation and Discussion</b>	<b>Anil Tombak</b>
10.50-11.00	<b>Future Perspectives</b>	<b>Salam Al-Kindi</b>
11.00-11.30	<b>COFFEE BREAK</b>	
11.30-12.50	<b>SESSION 4 - MM</b>	<b>CHAIRS: Claudio Cerchione - Evangelos Terpos(Virtual) - Tülin Tuğlular</b>
11.30-11.40	<b>How I Treat Relapsed Refractory Multiple Myeloma - CAR-T and Bispecific Antibodies</b>	<b>Claudio Cerchione</b>
11.40-11.50	<b>Mesurable Residual Disease(MRD) in the Era of Modern Therapies for the Treatment of Multiple Myeloma</b>	<b>Roberto Magalhaes</b>
11.50-12.05	<b>A Case of MM With Extramedullary Plasmacytoma Involving Optic Chiasm</b>	<b>Alpay Yeşilaltay</b>
12.05-12.20	<b>Management of Late Relapse With T-Cell Engagers</b>	<b>Alessandra Romano(Virtual)</b>
12.20-12.40	<b>Smoldering Myeloma” To Treat versus Not to Treat?</b>	<b>Claudio Cerchione(Yes) Evangelos Terpos (Virtual-No)</b>
12.40-12.50	<b>Future Perspectives</b>	<b>Roberto Magalhaes</b>
12.50-13.20	 <b>SATELLITE SYMPOSIUM</b> <b>”Ruxolitinib Experience in Myelofibrosis Treatment’</b> <b>Chair: Mustafa Nuri Yenerel</b> <b>Speaker: Elif Birtaş Ateşoğlu</b>	
13.20-14.20	<b>LUNCH BREAK</b>	
14.20-14.40	<b>Life Time Achivement Award Presentation: New Targeted Therapies in Acute Lymphoblastic Leukemia</b>	<b>Chair: Nilgün Sayınalp Speaker: Dieter Hoelzer</b>

14.40-16.00	<b>SESSION 5 - CML</b>	<b>CHAIRS: Naeem Chaudhri - Pia Raanani(Virtual) – A.Emre Eşkazan</b>
14.40-14.50	<b>CML 2023 - State of the Art and Cutting Edge Issues</b>	<b>Pia Raanani(Virtual)</b>
14.50-15.10	<b>Young, Intolerant and Resistant!</b>	<b>Carmen Fava(Virtual)</b>
15.10-15.30	<b>A Patient With Multipl TKI Failure</b>	<b>Deniz Özmen İbiş</b>
15.30-15.50	<b>Now that 2 gen TKIs are becoming generic, is still imatinib the best choice as first line therapy?</b>	<b>Giuseppe Saglio(Yes) - Tomasz Sacha(No)</b>
15.50-16.00	<b>Future Perspectives</b>	<b>Naeem Chaudhri</b>
16.00-17.20	<b>SESSION 6 - CLL</b>	<b>CHAIRS: Ahmad Ibrahim - Sevgi Kalayoğlu Beşişik</b>
16.00-16.10	<b>Treatment of CLL in 2023</b>	<b>Antonio Cuneo(Virtual)</b>
16.10-16.30	<b>Patient 1 - Presentation and Discussion</b>	<b>Argyris Symeonidis(Virtual)</b>
16.30-16.50	<b>Patient 2 - Presentation and Discussion</b>	<b>Fatma Eda Nuhoğlu Kantarcı</b>
16.50-17.10	<b>Combo Therapy Mono Therapy</b>	<b>Ahmad Ibrahim Gerardo Musuraca</b>
17.10-17.20	<b>Future Perspectives</b>	<b>Alessandra Ferrajoli(Virtual)</b>
17.20-17.50	<b>POSTER WALK WITH COFFEE BREAK Chair: Hüseyin Saffet Beköz</b>	
	<b>Reaction of the Circulating Regulatory T Cells After Chemoradiation Therapy of Hodgkin Lymphoma</b>	<b>Angelika Melnikova</b>
	<b>Infection Rates Across the Autologous Stem Cell Transplantation With Reflection of Multiple Myeloma Induction Story in Turkey</b>	<b>Simge Erdem</b>
	<b>Characterization and Management of Patients With Hereditary Factor X Deficiency: A Retrospective Single Center Experience</b>	<b>Nigar Abdullayeva</b>
	<b>Localized AI Amyloidosis of the Urinary Bladder Presenting With Painless Massive Hematuria</b>	<b>Kıvanç Koruk</b>
	<b>Syndrome of Inappropriate Antidiuretic Hormone Secretion As Central Nervous System Lymphoma Relapse Sign of Nodal Diffuse Large B-Cell Lymphoma</b>	<b>Nur Seda İbili Çetinkaya</b>
	<b>Development of Giant Plasmacytoma in a Patient With Bone Marrow Responce During Treatment: A Case Report</b>	<b>Rafiye Çiftçiler</b>

	<b>SESSION 7 - MPN'S</b>	<b>CHAIRS: Tariq Mughal - Rajko Kusec - Gülsüm Özet</b>
17.50-18.00	<b>State of the Art</b>	<b>Tariq Mughal</b>
18.00-18.20	<b>Patient 1 - Presentation and Discussion</b>	<b>Alessandro Lucchesi(Virtual)</b>
18.20-18.40	<b>Patient 2 - Presentation and Discussion</b>	<b>Selami Koçak Toprak(Virtual)</b>
18.40-19.00	<b>First-Line Treatment Choice for a Young PV Patient - HU vs. IFN</b>	<b>Rajko Kusec - A. Emre Eşkazan</b>
19.00-19.10	<b>Future Perspectives</b>	<b>Danilla Cilloni</b>

	<b>13 OCTOBER 2023</b>	
<b>08.10-08.50</b>	<b>ORAL COMMUNICATIONS SESSIONS (ADULT HEMATOLOGY)</b>	<b>Chair: Ferit Avcu</b>
08.10-08.20	<b>The Relationship Between Polycythemia Vera and Metabolic Syndrome: The Single Center Experience</b>	<b>Cem Selim</b>
08.20-08.30	<b>The Outcome of Peripheral T-Cell Lymphoma Patients Failing First-Line Therapy, From Prospective Cohort of T-Cell Brazil Project</b>	<b>Carmino De Souza(Virtual)</b>
08.30-08.40	<b>Global Research Patterns on Blood Donor Deferral: An Analysis of Themes, Trends, and Influence</b>	<b>Birol Güvenç</b>
08.40-08.50	<b>A Ghosal Hematodiaphyseal Dysplasia Case: Excellent Response to Non-Steroidal Anti-Inflammatory Drug Treatment</b>	<b>Hasan Fatih Çakmaklı</b>
<b>09.00-10.00</b>	<b>SESSION 8 - Indolent NHL</b>	<b>CHAIRS: Burhan Ferhanoglu - John Lister</b>
09.00-09.10	<b>Follicular Lymphoma</b>	<b>Burhan Ferhanoglu</b>
09.10-09.30	<b>Follicular Lymphoma - Predicting Aggressive Behavior and Treatment Options</b>	<b>John Lister</b>
09.30-09.50	<b>Is There Any Role of SCT in the New Era of Treatment Follicular Lymphoma?</b>	<b>Murat Özbalak (No) Sinem Civriz Bozdağ (Yes)</b>
09.50-10.00	<b>Future Perspectives</b>	<b>Stefano Luminari(Virtual)</b>
<b>10.00-10.20</b>	<b>Life Time Achievement Award Presentation - Survival After Failing ELN Milestones</b>	<b>Chair : Orhan Ayyıldız Speaker: Rudiger Hehlmann</b>
<b>10.20-10.50</b>	 <p><b>SATELLITE SYMPOSIUM</b> <b>"Clinical Presentation of PNH"</b></p> <p><b>Speakers: Tayfur Toptaş(PNH Diagnosis and Treatment)</b> <b>Anıl Tombak(PNH is an intravascular hemolysis disease)</b></p>	

10.50-11.20	<b>COFFEE BREAK</b>	
11.20-12.20	<b>SESSION 9 - Aggressive NHL</b>	<b>CHAIRS: Umberto Vitolo - Olga Meltem Akay</b>
11.20-11.30	<b>State of the Art of The Treatment of Aggressive Lymphomas</b>	<b>Umberto Vitolo</b>
11.30-11.50	<b>Transformed Follicular Lymphoma</b>	<b>Elif Birtaş Ateşoğlu</b>
11.50-12.10	<b>Role of ASCT in Treatment of R/R Lymphoma Patients in Resource Limited Countries</b>	<b>Adriatik Berisha</b>
12.10-12.20	<b>Future Perspectives</b>	<b>Gerardo Musuraca</b>
12.20-13.20	<b>SESSION 10 - HL</b>	<b>CHAIRS: Carmino De Souza(Virtual) – Leylagül Kaynar</b>
12.20-12.30	<b>Treatment of Classical Hodgkin Lymphoma</b>	<b>Carmino De Souza(Virtual)</b>
12.30-12.50	<b>Patient 1 - Presentation and Discussion</b>	<b>Shahla Shabanova</b>
12.50-13.10	<b>An Interim PET Positive Patient With Advanced Stage Hodgkin Lymphoma</b>	<b>Tayfur Toptaş</b>
13.10-13.20	<b>Future Perspectives</b>	<b>Irina Panovska(Virtual)</b>
13.20-14.20	<b>LUNCH BREAK</b>	
14.20-15.40	<b>SESSION 11 - MDS</b>	<b>CHAIRS: Moshe Mittelman(Virtual)- Mustafa Çetiner</b>
14.20-14.30	<b>State of the Art</b>	<b>Moshe Mittelman(Virtual)-</b>
14.30-14.50	<b>Optimizing the Management in Low Risk MDS</b>	<b>Uwe Platzbecker(Virtual)</b>
14.50-15.10	<b>Patient 2 - Presentation and Discussion</b>	<b>Mustafa Çetiner</b>
15.10-15.30	<b>Patient with Polycythemia, Thrombocytopenia and Bone Marrow Failure with A Familial Hematologic Disease</b>	<b>Moshe Mittelman(Virtual)</b>
15.30-15.40	<b>Future Perspectives</b>	<b>Guillermo Garcia Manero(Virtual)</b>
15.40-16.10		
	<b>IDEOGEN AG SATELLITE SYMPOSIUM</b> <b>Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma with Pralatrexate and Belinostat</b>	
	<b>Chair: Giuseppe Gritti</b>	
	<b>Speaker: Ali Ünal (Clinical Outcomes and T-Follicular Helper Phenotype Response with Belinostat in PTCL)</b>	
	<b>Speaker: Owen A. O'Connor (A 20-Year Journey into the Development of Pralatrexate: What's Next?)</b>	
16.10-16.30	<b>Life Time Achievement Award Presentation: A 50 Year Personal Perspective on the Treatment of Acute Leukemia</b>	<b>Chairs : Zafer Gülbaş Speaker: Charles Schiffer</b>

<b>16.30-17.30</b>	<b>SESSION 12 - COAGULOPATHIES</b>	<b>CHAIR: Drew Provan – Bülent Antmen</b>
16.30-16.40	<b>State of the Art</b>	<b>Drew Provan</b>
16.40-17.00	<b>Patient 1 - Presentation and Discussion</b>	<b>Bülent Antmen</b>
17.00-17.20	<b>Patient 2 - Presentation and Discussion</b>	<b>Defne Ay Tuncel</b>
17.20-17.30	<b>Future Perspective</b>	<b>Güray Saydam(Virtual)</b>
<b>17.30-18.00</b>	<b>POSTER WALK WITH COFFEE BREAK</b> <b>Chair :Vahap Okan</b>	
	<b>Can Radiotherapy Induce a Clinical Response With Occasional Long-Term Remission In Recurrent Granulosa Cell Tumors of the Ovary?</b>	<b>Ibtehaj Taher Hassan</b>
	<b>Azerbaijan Experience of Haemophilia Care.</b>	<b>Gunel Alizade</b>
	<b>Autologous Hematopoietic Cell Transplantation (Hct) For Hodgkin Lymphoma, Real World Experience of a Single Center Experience.</b>	<b>Carmino De Souza(Virtual)</b>
	<b>A Phase 3 Study To Evaluate the Efficacy and Safety of Caplacizumab Without First-Line Therapeutic Plasma Exchange in Adults With Immune-Mediated Thrombotic Thrombocytopenic Purpura</b>	<b>Özgüç Semih Şimşir</b>
<b>18.00-19.10</b>	<b>SESSION 13 - RARE ENTITIES</b>	<b>CHAIRS: Hanan Hamed – Mustafa Nuri Yenerel</b>
18.00-18.15	<b>Clinical Case of Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN</b>	<b>Hanan Hamed</b>
18.15-18.30	<b>Clinical Case of Mastocytosis</b>	<b>Daniela Cilloni</b>
18.30-18.45	<b>Hereditary Hemolytic Anemias:Red Cell Membrane Defects New Insights</b>	<b>Achilles Iolascon(Virtual)</b>
18.45-19.00	<b>Clinical Case of PNH</b>	<b>Mustafa Nuri Yenerel</b>
19.00-19.10	<b>Discussion</b>	<b>All</b>

# 14 OCTOBER 2022

	<b>14 OCTOBER 2022</b>	
08.10-08.50	<b>ORAL COMMUNICATIONS SESSIONS Chair: Ali Ünal</b>	
08.10-08.20	Long-Term Outcomes of Allogeneic Stem Cell Transplantation For Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma: Multi-Center Experience From Turkey	Ayşe Uysal
08.20-08.30	Ibrutinib-Obinutuzumab Combination Therapy in the Treatment of Relapsed Nodal Marginal Zone Lymphoma: A Case Study	Nuray Gül Açar(Virtual)
08.30-08.40	Real-World (RW) Treatment Patterns and Outcomes in Patients (PTS) with Relapsed/Refractory Multiple Myeloma (RRMM) with at Least One Prior Therapy in Turkey	Özgür Pektaş
09.00-10.00	<b>SESSION 14 - SUPPORTIVE CARE</b>	<b>CHAIRS: Claudio Cerchione - Mustafa Çetiner - Mehmet Sönmez</b>
09.00-09.15	Febrile Neutropenia	Şiran Keske
09.15-09.30	Anemia and Transfusion-Medicine	Biol Güvenç
09.30-09.45	Pain Management	Halil Çetingök
09.45-10.00	The "Problem" of Survivors: How to Manage Them and How to Monitor Long-Term Adverse Events	Ajai Chari(Virtual)
10.00-10.20	Life Time Achievement Award Presentation:	Chair: Şehmus Ertop Speaker: Hagop Kantarjian(Virtual)
10.20-10.50	<b>SATELLITE SYMPOSIUM</b> "Open a New Dimension in Multiple Myeloma Treatment with Darzalex" Chair:Birol Güvenç Speaker:Şebnem İzmir Güner	
10.50-11.20	<b>POSTER WALK WITH COFFEE BREAK</b> Chair : Demet Çekdemir	
	Cutaneous Richter Transformation in the 16th Year of Follicular Lymphoma Diagnosis	Ulviyya Hasanzade
	Retrospective Evaluation of Bone Marrow Findings in Autoimmune Hemolytic Anemias	Eren Arslan Davulcu
	Reactivation of Hepatitis B in a Patient With Untreated Chronic Lymphocytic Leukemia	Sinan Demircioğlu
	Ibrutinib Related Neuropathy: A Case Report	Zeynep Tuğba Güven
	A Rare Intersection: Coexistence of Breast Cancer and Sickle Cell Disease in A 40 - Year-Old Female - A Case Report	İdil Yürekli



11.20-11.50	 <p style="text-align: center;"><b>SATELLITE SYMPOSIUM</b>  <b>"Reblozyl changes the blood transfusion needs for patients with beta thalassemia and MDS "</b>  <b>Chair: Birol Güvenç</b>  <b>Speakers: Mustafa Çetiner - Bülent Antmen</b></p>	
11.50-12.40	<b>SESSION 15 - BONE MARROW FAILURE</b>	<b>CHAIRS: Ahmad Ibrahim – Işık Kaygusuz Atagündüz</b>
11.50-12.10	<b>Aplastic Anemia</b>	<b>Régis Peffault de Latour(Virtual)</b>
12.10-12.30	<b>Severe Aplastic Anemia</b>	<b>Ahmet Mert Yanık</b>
12.30-12.40	<b>Future Perspectives</b>	<b>Régis Peffault de Latour(Virtual)</b>
12.40-13.00	<b>Life Time Achivement Award Presentation- Key Factors For the Success of Clinical Research Networks in Myeloproliferative</b>	<b>Chair : Siret Ratip Speaker: Tiziano Barbui</b>
13.00-14.00	<b>LUNCH BREAK</b>	
14.00-15.30	<b>SESSION 16 - CELLULAR THERAPY</b>	<b>CHAIRS: Jean François Rossi– Elif Birtaş Ateşoğlu</b>
14.00-14.20	<b>The Future of Cell Therapy of Haematologic Cancers</b>	<b>Robert Peter Gale</b>
14.20-14.40	<b>A Pivotal Study Report of CNCT19 (Inaticabtagene Autoleucel) Treatment in Adult R/R B-cell ALL in China.</b>	<b>Lv Lulu (Virtual)</b>
14.40-15.00	<b>Dendritic Cells in Oncology</b>	<b>Angelika Melnikova</b>
15.00-15.10	<b>Stem Cell Transplantation in Solid Oncology. A Clinical Case</b>	<b>Anastasia Mamonova</b>
15.10-15.25	<b>Adoptive Immunotherapy in Oncology</b>	<b>Lyudmila Grivtsova</b>
15.25-15.30	<b>Conclusions</b>	<b>Jean François Rossi</b>
15.30-16.45	<b>SESSION 17 - AI IN MEDICINE</b>	<b>CHAIRS: Moshe Mittelman(Virtual) – Mehmet Ali Özcan</b>
15.30-15.40	<b>Introductory Presentation</b>	<b>Moshe Mittelman (Virtual)-</b>
15.40-16.00	<b>The Application of AI to Thrombocytopenia</b>	<b>Drew Provan</b>
16.00-16.30	<b>CPi-Clalit Proactive and Preventative Intervention</b>	<b>Doron Netzer(Virtual)</b>
16.30-16.45	<b>Discussion</b>	<b>All</b>
16.45	<b>CLOSING REMARKS OF EHOC 2023</b>	